Introduction to Foundayo
Eli Lilly’s weight loss pill, Foundayo, has received approval from the Federal Food and Drug Administration (FDA). This new medication is positioned as a competitor to GLP-1 weight loss drugs produced by other major pharmaceutical companies, such as Novo Nordisk. The drug is designed for adults with obesity, those who are overweight, or individuals with weight-related health conditions. It can be taken at any time of day without restrictions on food or water intake.
How Does Foundayo Compare to Other GLP-1s?
GLP-1 medications have transformed the landscape of weight loss treatment since the early 2020s. Initially developed for type 2 diabetes, these drugs have found applications in treating various obesity-related conditions. Most GLP-1s have been available as injections rather than pills. The FDA’s approval of Foundayo introduces a new option for patients, offering greater flexibility compared to competitors.
Novo Nordisk, which produces Ozempic, introduced the first oral semaglutide pill for type 2 diabetes treatment in 2019, called Rybelsus. This pill must be taken each morning with a small amount of water on an empty stomach. Oral Wegovy, also made by Novo Nordisk, became available for weight loss in early 2026, and the company plans to release a pill form of Ozempic soon. In contrast, Foundayo can be taken at any time of day and has been approved for generalized weight loss-related use.
A trial published by The Lancet showed that patients taking Foundayo lost more weight compared to those on Rybelsus. However, Novo Nordisk pointed out that the study focused on lower doses of semaglutide, not the higher doses used for weight loss.
Insurance Coverage for Foundayo
Insurance coverage for Foundayo varies depending on the plan. Private insurance plans may cover GLP-1s for those with a type 2 diabetes diagnosis, while others may require prior authorization from a doctor or completion of health assessments. Marketplace plans typically have similar rules, rarely covering GLP-1s for weight loss.
Government-run insurance plans, like Medicare and Medicaid, usually do not cover weight-loss drugs. However, Medicare Part D enrollees may be able to get the pill for $50 per month starting July 1, according to Lilly. Insurers will evaluate coverage this summer before the 2027 open enrollment begins, providing a clearer picture of coverage options by fall.
The insurance conversation around GLP-1s has become complex, with some insurers rolling back coverage due to rising costs. A GoodRx analysis found that the number of Americans without coverage for Eli Lilly’s Zepbound increased by 12% from 2025 to 2026.
Cost of the Pill
Eli Lilly announced that the highest dose of Foundayo will be available for $349. Oral Wegovy, by contrast, costs $299 at the high dose. At the lowest dose, patients can get the drug for $149 with their self-pay option, or $25 with commercial insurance and a Foundayo savings card.
The rise of GLP-1s has led to a growing direct-to-consumer industry. LillyDirect, Eli Lilly’s self-pay platform, partners with Walmart, Amazon, and telehealth companies like Ro. More consumers are exploring cash options, bypassing insurance, and shopping around for the best price.
Side Effects of the Pill
Like other GLP-1 medications, Foundayo can cause side effects. Common side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, and hair loss. Rare but serious side effects include inflammation of the pancreas, dehydration, severe stomach problems, and allergic reactions.
Patients are advised to take the pill under medical supervision, take only one pill a day, and avoid using it with other GLP-1s. Trials showed that participants on Foundayo experienced more side effects and were less likely to stay on the medication compared to those using Rybelsus.
Future of GLP-1s
GLP-1s are still a relatively new medical treatment, and long-term research is limited. Studies suggest they could help alleviate symptoms of sleep apnea, arthritis, heart disease, and addiction. More clinical trials could lead to broader approvals.
The insurance battle between drugmakers, insurers, and employers is expected to escalate as demand for GLP-1s grows, driving up healthcare costs. Maintaining health benefits and avoiding rapid weight regain requires long-term use of these drugs, which could be expensive but offer potential preventative healthcare benefits.
